Dr. Philip Rosenfeld presents the results of this phase 2 study:

Safety

• There was no safety signal that would preclude continued investigation.
• After extensive MRI monitoring, amyloid-related imaging abnormalities, edema detected, were low (< 1%).

PK/PD

• Exposure to GSK933776 increased proportional to dose.
• Free Aβ decreased with near maximum reduction observed in the 15 mg/kg arm.

Efficacy

• There was no slowing of GA enlargement rate with GSK933776 in the primary analysis or among prospectively defined subpopulations.
• There was no clinically meaningful slowing of decline relative to placebo in visual function measures.

Pharmacogenetics and Low Luminance Deficits

• "CFI" genetic biomarker (rs17440077) status did not have a have a significant affect on GA enlargement rate.
• LLVA deficit at BL correlated with GA enlargement rate overall.